IBAB Ion Beam Applications SA

IBA – Transparency Notification

IBA – Transparency Notification

Louvain-la-Neuve, Belgium, February 18, 2020, 17.30

Summary of the notification

IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 17, 2020.

In its notification, Norges Bank has notified, that following an acquisition of IBA shares with voting rights and a disposal of equivalent financial instruments, its total holding in IBA SA remains the same as in its previous notification but its holding in voting rights has crossed upwards the 3% threshold on February 14, 2020.

In details, on February 14, 2020, Norges Bank owned (A) 961.258 IBA shares with voting rights (versus 707.489 shares in its previous notification), representing 3.19 % of the total number of shares issued by IBA (30 133 920) (versus 2.35% in its previous notification), as well as (B) 447.811 equivalent financial instruments (versus 701.580 in its previous notification) representing 1.49% of the total number of shares issued by IBA (30 133 920) (versus 2.33% in its previous notification).

Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights
  • Persons subject to the notification requirement: Norges Bank
  • Date on which the threshold is crossed: 14/02/2020
  • Threshold crossed (in %): 3%
  • Denominator: 30 133 920
  • Notified details: (extract of the received notification form)

           

A) Voting rightsPrevious notificationAfter the transaction 
 # of voting rights# of voting rights% of voting rights 
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities 
Norges Bank707.489961.258 3.19%  
 TOTAL961.25803.19%0,00% 
       
B) Equivalent financial instrumentsAfter the transaction
Holder of equivalent financial instruments Type of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
Norges BankShares on loan (right to recall) At any time447.8111.49 %physical
 TOTAL 447.8111.49 % 
       
 TOTAL (A & B)  # of voting rights%of voting rights 
    1.409.0694,68% 
  • Full chain of controlled undertakings through which the holding is effectively held

Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway’s foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.

For further information, please contact:

IBA

Elodie Jaumain

Paralegal

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

Attachment

EN
18/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

Procès-verbal de l'Assemblée Générale Ordinaire d'IBA et résultats des...

Procès-verbal de l'Assemblée Générale Ordinaire d'IBA et résultats des votes Information réglementée Assemblée Générale Ordinaire du 11 juin 2025 Belgique, le 16 juin 2025 (17h50) – Ion Beam Applications SA (« IBA ») annonce que l’ensemble des résolutions proposées à ses actionnaires lors de l’Assemblée Générale Ordinaire tenue le 11 juin dernier ont été adoptées à l’unanimité. Parmi celles-ci figurent notamment : L’approbation des comptes annuels pour l’exercice clôturé le 31 décembre 2024 ;L’approbation de la proposition de dividende de 0,24 EUR par action.  Calendrier rel...

 PRESS RELEASE

World's Leading Institutions and IBA launch Proton Therapy Academy to ...

World's Leading Institutions and IBA launch Proton Therapy Academy to shape the future of cancer care New global education initiative unveiled at 2025 PTCOG Annual Conference Louvain-la-Neuve, Belgium, 4 June 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces the launch of Proton Therapy Academy, a new global training and education initiative developed in partnership with prominent institutions in the field of proton therapy. The Academy has be...

 PRESS RELEASE

Des institutions mondiales de renom et IBA lancent la Proton Therapy A...

Des institutions mondiales de renom et IBA lancent la Proton Therapy Academy pour élaborer l'avenir des soins contre le cancer Nouvelle initiative mondiale de formation présentée lors de la conférence annuelle PTCOG 2025 Louvain-la-Neuve, Belgique, le 4 juin 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, annonce aujourd'hui le lancement de la Proton Therapy Academy, une nouvelle initiative de formation et d’éducation développée en parte...

 PRESS RELEASE

Iba – Acquisition of Own Shares - Completion of the Share Buyback Prog...

Iba – Acquisition of Own Shares - Completion of the Share Buyback Program Immediate Release – May 30th, 2025 Louvain-la-Neuve, Belgium, May 30th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until Decembe...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES - FIN DU PROGRAMME DE RACHAT D’ACT...

IBA – ACQUISITION D’ACTIONS PROPRES - FIN DU PROGRAMME DE RACHAT D’ACTIONS Publication immédiate – 30 mai 2025 Louvain-la-Neuve, Belgique, 30 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 24 mars 2025. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 650.000 actions ordinaires IBA selon les termes d'...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch